down arrow

Design Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US25056L1035
USD
9.82
0.88 (9.84%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

9.3310.02

52 Week

2.6010.02
Valuation
Technical
Day's Volume

CASH

320.15 k

Shareholding (Jun 2025)

FII

1.76%

Held by 40 FIIs

DII

70.92%

Held by 16 DIIs

Promoter

15.98%

How big is Design Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Design Therapeutics, Inc. has a market capitalization of 208.91 million and reported net sales of 0.00 million with a net profit of -56.19 million over the latest four quarters. Shareholder's funds are 242.10 million, and total assets amount to 252.09 million.

As of Jun 18, Design Therapeutics, Inc. has a market capitalization of 208.91 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -56.19 million during the same period.<BR><BR>As of Dec'24, the reporting period shows shareholder's funds of 242.10 million and total assets amounting to 252.09 million.

Read More

What does Design Therapeutics, Inc. do?

22-Jun-2025

Design Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $208.91 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -24.66%.

Overview:<BR>Design Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 208.91 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.00<BR>Return on Equity: -24.66%<BR>Price to Book: 0.92<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Design Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Design Therapeutics, Inc. has shifted to a bullish trend with strong weekly indicators, outperforming the S&P 500 in the short term but significantly underperforming over the past three years.

As of 10 September 2025, the technical trend for Design Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators, particularly in the weekly MACD and Bollinger Bands, both of which are bullish. Daily moving averages also support this bullish outlook. The KST shows a mixed signal with a weekly bullish and monthly mildly bearish stance, while the OBV indicates a mildly bullish trend. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 4.87% and 15.74% respectively, compared to the S&P 500's 1.05% and 2.33%. However, over the longer term, the stock has significantly underperformed the benchmark, with a 3-year return of -71.32% versus the S&P 500's 70.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 331 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-29.80%

stock-summary
Price to Book

1.56

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
64.77%
0%
64.77%
6 Months
144.89%
0%
144.89%
1 Year
63.94%
0%
63.94%
2 Years
291.24%
0%
291.24%
3 Years
-29.86%
0%
-29.86%
4 Years
-37.61%
0%
-37.61%
5 Years
0%
0%
0.0%

Design Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Design Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Design Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators, particularly in the weekly MACD and Bollinger Bands, both of which are bullish. Daily moving averages also support this bullish outlook. The KST shows a mixed signal with a weekly bullish and monthly mildly bearish stance, while the OBV indicates a mildly bullish trend. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 4.87% and 15.74% respectively, compared to the S&P 500's 1.05% and 2.33%. However, over the longer term, the stock has significantly underperformed the benchmark, with a 3-year return of -71.32% versus the S&P 500's 70.41%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-222.30%
EBIT to Interest (avg)
-53.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.93%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.00
EV to EBIT
0.02
EV to EBITDA
0.02
EV to Capital Employed
1.21
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6840.10%
ROE (Latest)
-24.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 32 Schemes (11.34%)

Foreign Institutions

Held by 40 Foreign Institutions (1.76%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -61.86% vs 40.70% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.40",
          "val2": "-14.90",
          "chgp": "-43.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.10",
          "val2": "-11.80",
          "chgp": "-61.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.86% vs -5.69% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-61.80",
          "val2": "-77.70",
          "chgp": "20.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.60",
          "val2": "-66.90",
          "chgp": "25.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.40
-14.90
-43.62%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.10
-11.80
-61.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -61.86% vs 40.70% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-61.80
-77.70
20.46%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-49.60
-66.90
25.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 25.86% vs -5.69% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Design Therapeutics, Inc. stock-summary
stock-summary
Design Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."